Prof. Weiling He | Cancer Genomics Computational Studies | Best Researcher Award
Professor at Xiamen University, China
Dr. Weiling He is a leading figure in precision oncology, serving as Chief Physician, Professor, Doctoral and Postdoctoral Supervisor, and President of Xiang’an Hospital at Xiamen University. He is widely recognized for his contributions to cancer treatment, particularly in the domains of tumor microenvironments and drug resistance. Honored with the National Natural Science Foundation of China’s Excellent Young Scientist Fund and recognized as a Distinguished Young Medical Talent of Guangdong Province, Dr. He has established himself as a trailblazer in translational medical research. His prolific output includes over 50 SCI-indexed publications and six granted patents, underscoring his influence in both academia and clinical application.
Profile
Education
Dr. He holds both an MD and a PhD, equipping him with a robust foundation for navigating the complex landscape of cancer research and treatment. His academic journey reflects a commitment to scientific excellence and multidisciplinary learning, enabling him to bridge the gap between theoretical research and clinical practice. The integration of medicine and scientific inquiry during his training shaped his ongoing work in precision medicine, translational oncology, and systems biology.
Experience
With a career marked by leadership and innovation, Dr. He currently serves as the President of Xiang’an Hospital at Xiamen University. He has led more than 20 research projects at the national and provincial levels, including prestigious programs under the National Key R&D Initiative and the National Natural Science Foundation of China. Dr. He has also contributed extensively to industry-academia collaboration, participating in strategic projects like the Guangdong Soft Science Program and the Guangzhou Future Industry Initiative. His academic affiliations include leadership roles in over ten national medical associations, reflecting a deep engagement with both clinical and academic ecosystems.
Research Interest
Dr. He’s research focuses on unraveling the mechanisms of tumor drug resistance, exploring metastasis pathways, and analyzing the tumor microenvironment. He is particularly interested in precision interventional therapy and the development of biomaterials and microfluidic technologies for real-time monitoring and treatment. His interdisciplinary approach combines oncology, engineering, and systems biology to improve the outcomes of metastatic cancer therapies. Through collaborative research with institutions such as Sun Yat-sen University and Emory University, he advances new methodologies in clinical translation and integrative cancer treatment.
Award
Dr. Weiling He has received several distinguished honors throughout his career. Among them, the National Natural Science Foundation of China awarded him the Excellent Young Scientist Fund, recognizing his outstanding potential and research impact in oncology. In addition, he was named a Distinguished Young Medical Talent of Guangdong Province, affirming his influence on medical innovation and leadership. His work is frequently acknowledged in national and international forums, and he has played a pivotal role in advancing precision medicine initiatives across China.
Publication
Dr. He has authored more than 50 papers indexed in SCI journals, with several appearing in top-tier publications. Notable recent works include:
“Immune Microenvironment Remodeling in Colorectal Cancer,” Cancer Immunology Research, 2020 – cited 326 times.
“Dual Nanoparticle Delivery in Precision Oncology,” Advanced Science, 2021.
“Microfluidic Chips for Real-time Tumor Monitoring,” Nature Communications, 2022.
“Translational Biomaterials in Interventional Therapy,” Science Translational Medicine, 2023 (cover article).
“Integrated Oncology Systems for Drug Resistance,” Nature Cancer, 2023.
“Microsphere Technology for Metastatic Cancer,” Advanced Science, 2024.
“Tumor Sensitization Targets for Interventional Therapy,” Nature Communications, 2024.
These publications have garnered over 1000 citations in total, with multiple works recognized as “Highly Cited Papers” in their respective fields.
Conclusion
Dr. Weiling He’s exceptional academic record, impactful research, numerous high-impact publications, robust patent portfolio, and her pivotal role in the advancement of precision oncology mark her as a standout candidate for the Best Researcher Award. Her commitment to interdisciplinary innovation and translational impact makes her not only deserving of this honor but a role model for future generations in computational and medical biology.